182 related articles for article (PubMed ID: 19005972)
1. Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma.
Seren S; Mutchnick M; Hutchinson D; Harmanci O; Bayraktar Y; Mutchnick S; Sahin K; Kucuk O
Nutr Cancer; 2008; 60(6):729-35. PubMed ID: 19005972
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
Ueno Y; Sollano JD; Farrell GC
J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
[TBL] [Abstract][Full Text] [Related]
3. Phytochemicals in hepatocellular cancer prevention.
Nishino H
Nutr Cancer; 2009; 61(6):789-91. PubMed ID: 20155617
[TBL] [Abstract][Full Text] [Related]
4. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
Schott E; Bergk A; Berg T
Z Gastroenterol; 2008 Jan; 46(1):69-80. PubMed ID: 18188819
[TBL] [Abstract][Full Text] [Related]
5. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C and hepatocellular carcinoma.
Di Bisceglie AM
Hepatology; 1997 Sep; 26(3 Suppl 1):34S-38S. PubMed ID: 9305661
[TBL] [Abstract][Full Text] [Related]
7. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
8. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
Masuzaki R; Yoshida H; Omata M
Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma
J Gastroenterol Hepatol; 2010 Apr; 25(4):657-63. PubMed ID: 20492323
[TBL] [Abstract][Full Text] [Related]
10. Effect of vitamin K2 on the development of hepatocellular carcinoma in type C cirrhosis.
Kojima K; Tamano M; Akima T; Hashimoto T; Kuniyoshi T; Maeda C; Majima Y; Kusano K; Murohisa T; Iijima M; Hiraishi H
Hepatogastroenterology; 2010; 57(102-103):1264-7. PubMed ID: 21410069
[TBL] [Abstract][Full Text] [Related]
11. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
12. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer.
Kataria Y; Deaton RJ; Enk E; Jin M; Petrauskaite M; Dong L; Goldenberg JR; Cotler SJ; Jensen DM; van Breemen RB; Gann PH
BMC Gastroenterol; 2016 Feb; 16():30. PubMed ID: 26927700
[TBL] [Abstract][Full Text] [Related]
13. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
14. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
Pekow JR; Bhan AK; Zheng H; Chung RT
Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study on relationship between hepatocellular carcinoma and hepatitis C virus infection in patients with chronic liver disease].
Sata M; Tokeshi S; Nakano H; Majima Y; Tanikawa K
Rinsho Byori; 1992 Sep; 40(9):929-34. PubMed ID: 1279247
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
El-Bassiouni A; Nosseir M; Zoheiry M; El-Ahwany E; Ghali A; El-Bassiouni N
APMIS; 2006 Jun; 114(6):420-7. PubMed ID: 16856963
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Takemura S; Shiomi S; Kinoshita H
Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
[TBL] [Abstract][Full Text] [Related]
18. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of hepatocellular carcinoma.
Omata M; Yoshida H
Liver Transpl; 2004 Feb; 10(2 Suppl 1):S111-4. PubMed ID: 14762850
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma.
Bishayee A; Politis T; Darvesh AS
Cancer Treat Rev; 2010 Feb; 36(1):43-53. PubMed ID: 19910122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
